Hyperoxia-mediated oxidative stress increases expression of UCP3 mRNA and protein in skeletal muscle

Department of Cell Physiology and Metabolism, Centre Médical Universitaire, 1 rue Michel Servet, 1211 Geneva 4, Switzerland.
FEBS Letters (Impact Factor: 3.17). 07/2005; 579(16):3411-5. DOI: 10.1016/j.febslet.2005.04.084
Source: PubMed


The uncoupling protein-3 (UCP3) is a mitochondrial protein expressed mainly in skeletal muscle. Among several hypotheses for its physiological function, UCP3 has been proposed to prevent excessive production of reactive oxygen species. In the present study, we evaluated the effect of an oxidative stress induced by hyperoxia on UCP3 expression in mouse skeletal muscle and C2C12 myotubes. We found that the hyperoxia-mediated oxidative stress was associated with a 5-fold and 3-fold increase of UCP3 mRNA and protein levels, respectively, in mouse muscle. Hyperoxia also enhanced reactive oxygen species production and UCP3 mRNA expression in C2C12 myotubes. Our findings support the view that both in vivo and in vitro UCP3 may modulate reactive oxygen species production in response to an oxidative stress.

Download full-text


Available from: Constance Barazzone-Argiroffo, May 20, 2015
  • Source
    • "Oxygen itself acts as a free radical [30], and a high oxygen tension is correlated with the production of ROS. Thus, detection of ROS implies the existence of oxidative stress [37] [38], and such oxidative stress is induced in proportion to the oxygen tension [36] [39] [40]. We confirmed that the hyperoxic culture medium had a 2-fold higher ROS content than the normoxic medium in our vitro study (data not shown). "

    Full-text · Dataset · Mar 2014
  • Source
    • "Proteomic analysis of C2C12 cells indicates that respiratory chain proteins are up-regulated by 10 days postdifferentiation (Kislinger et al. 2005), resulting in increased potential for generation of oxidative stress. This is countered, in part, by up-regulation of uncoupling protein-3 (Flandin et al. 2005). Given that these data illustrate the importance of managing the increased oxidative stress that can be generated by differentiated skeletal muscle, our data indicating residual telomerase activity in post-mitotic cells suggests a potential role for telomerase, independent of its role in maintaining telomeric structure. "

    Full-text · Dataset · Nov 2013
  • Source
    • "Furthermore, induction of both Ucp2 and Ucp3 has also been shown previously to be induced by β-AR signaling in exercising skeletal muscle [27,76-78]. Since Ucp3 and Ucp2 have been implicated in the reduction of ROS [79,80], it is possible that the induction of Ucp3 and Ucp2 expression in skeletal muscle is one mechanism for reducing ROS production during or after exercise. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic administration of beta-adrenoceptor (beta-AR) agonists has been found to induce skeletal muscle hypertrophy and significant metabolic changes. In the context of energy homeostasis, the importance of beta-AR signaling has been highlighted by the inability of beta(1-3)-AR-deficient mice to regulate energy expenditure and susceptibility to diet induced obesity. However, the molecular pathways and gene expression changes that initiate and maintain these phenotypic modulations are poorly understood. Therefore, the aim of this study was to identify differential changes in gene expression in murine skeletal muscle associated with systemic (acute and chronic) administration of the beta(2)-AR agonist formoterol. Skeletal muscle gene expression (from murine tibialis anterior) was profiled at both 1 and 4 hours following systemic administration of the beta(2)-AR agonist formoterol, using Illumina 46K mouse BeadArrays. Illumina expression profiling revealed significant expression changes in genes associated with skeletal muscle hypertrophy, myoblast differentiation, metabolism, circadian rhythm, transcription, histones, and oxidative stress. Differentially expressed genes relevant to the regulation of muscle mass and metabolism (in the context of the hypertrophic phenotype) were further validated by quantitative RT-PCR to examine gene expression in response to both acute (1-24 h) and chronic administration (1-28 days) of formoterol at multiple timepoints. In terms of skeletal muscle hypertrophy, attenuation of myostatin signaling (including differential expression of myostatin, activin receptor IIB, phospho-Smad3 etc) was observed following acute and chronic administration of formoterol. Acute (but not chronic) administration of formoterol also significantly induced the expression of genes involved in oxidative metabolism, including hexokinase 2, sorbin and SH3 domain containing 1, and uncoupling protein 3. Interestingly, formoterol administration also appeared to influence some genes associated with the peripheral regulation of circadian rhythm (including nuclear factor interleukin 3 regulated, D site albumin promoter binding protein, and cryptochrome 2). This is the first study to utilize gene expression profiling to examine global gene expression in response to acute beta(2)-AR agonist treatment of skeletal muscle. In summary, systemic administration of a beta(2)-AR agonist had a profound effect on global gene expression in skeletal muscle. In terms of hypertrophy, beta(2)-AR agonist treatment altered the expression of several genes associated with myostatin signaling, a previously unreported effect of beta-AR signaling in skeletal muscle. This study also demonstrates a beta(2)-AR agonist regulation of circadian rhythm genes, indicating crosstalk between beta-AR signaling and circadian cycling in skeletal muscle. Gene expression alterations discovered in this study provides insight into many of the underlying changes in gene expression that mediate beta-AR induced skeletal muscle hypertrophy and altered metabolism.
    Full-text · Article · Sep 2009 · BMC Genomics
Show more